Japan Chemical Research Looks To Grow Market Shares For Growth Hormone Products
This article was originally published in PharmAsia News
Executive SummaryJapan Chemical Research 2008 sales increased by 1.8 percent to ¥12.82 billion, through growth of the company's major product, human growth hormone Growject (somatropin). For fiscal year 2009, the company estimates a 1.8 percent increase in sales and 8 percent increase in income. JCR submitted a new drug application in Japan for recombinant erythropoietin to treat nephrogenic anemia last November, aiming for a market launch in 2010. JCR also begins clinical trials for its mesenchymal stem cell therapeutic agent in Japan. (Click here for more - Japanese language
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.